WARFARIN: PLACE IN THE ANTICOAGULANT THERAPY TODAY
A trial fibrillation is the most common cardiac source of systemic emboli and car-a significant reduction or even blockage of dioembolic stroke. Anticoagulants are recommended for preventing stroke in patients with non-valvular atrial fibrillation. Warfarin reduces the risk of stroke in patients w...
Main Authors: | N. A. Novikova, A. N. Volovchenko |
---|---|
Format: | Article |
Language: | Russian |
Published: |
«REMEDIUM GROUP» Ltd.
2016-07-01
|
Series: | Атеротромбоз |
Subjects: | |
Online Access: | https://www.aterotromboz.ru/jour/article/view/80 |
Similar Items
-
NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY
by: D. A. Napalkov, et al.
Published: (2015-09-01) -
ANTICOAGULANT THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: DRUG CHOICE AND DOSAGE ADJUSTMENT
by: E. L. Dolgova, et al.
Published: (2015-09-01) -
ANALYSIS OF THE INFLUENCE OF THROMBOEMBOLIC COMPLICATIONS PREVENTION WITH ORAL ANTICOAGULANTS ON BUDGET IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION
by: A. V. Rudakova
Published: (2015-09-01) -
COMPARATIVE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS
by: V. A. Sulimov, et al.
Published: (2015-09-01) -
СНИЖЕНИЕ РИСКА СЕРДЕЧНО-СОСУДИСТОЙ СМЕРТНОСТИ И ИНСУЛЬТА У ПАЦИЕНТОВ С ФИБРИЛЛЯЦИЕЙ ПРЕДСЕРДИЙ
Published: (2016-12-01)